A5064150614- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV-related health complications and treatments
- Reproductive tract infections research
- Adolescent Sexual and Reproductive Health
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV, Drug Use, Sexual Risk
- Ethics in Clinical Research
University of the Witwatersrand
2017-2024
Centre for the AIDS Programme of Research in South Africa
2010-2011
University of KwaZulu-Natal
2011
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed effectiveness and safety a 1% vaginal gel formulation tenofovir, nucleotide reverse transcriptase inhibitor, prevention HIV acquisition women. A double-blind, randomized controlled was conducted comparing tenofovir (n = 445 women) with placebo 444 sexually active, HIV-uninfected 18- to 40-year-old women urban rural KwaZulu-Natal, Africa. serostatus, safety, sexual behavior, condom use were at monthly...
Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There limited data on their use low- middle-income countries.
Abstract Background ADVANCE compared 3 World Health Organization–recommended first-line regimens in participants with HIV who were antiretroviral naive. Methods This randomized, open-label, noninferiority trial enrolled living no exposure the previous 6 months to 1 of following arms: tenofovir alafenamide (TAF) / emtricitabine (FTC) + dolutegravir (DTG) (2 tablets), disoproxil fumarate (TDF) FTC DTG or a fixed-dose combination TDF efavirenz (EFV) (1 tablet). We report final safety and...
Abstract Background Young women in sub-Saharan Africa bear a disproportionate burden of HIV infection compared to men but have limited options reduce their risk. Microbicides could fill an important prevention gap for sexually active who are unable successfully negotiate mutual monogamy or condom use. Purpose This paper describes the baseline sample characteristics CAPRISA 004 trial which assessed safety and effectiveness vaginal microbicide, 1% tenofovir gel South Africa. Methods analysis...
Reducing doses of antiretroviral drugs, including stavudine (d4T), may lower toxicity, while preserving efficacy. There are substantial concerns about renal and bone toxicities tenofovir disoproxil fumarate (TDF).HIV-1-infected treatment-naive adults in India, South Africa, Uganda.A phase-4, 96-week, randomized, double-blind, noninferiority trial compared d4T 20 mg twice daily TDF, taken combination with lamivudine (3TC) efavirenz (EFV). The primary endpoint was the proportion participants...
Although eligibility for antiretroviral treatment is no longer based on CD4 thresholds, testing remains important. Variation in cell count complicates initiation of antibiotic prophylaxis, differential diagnoses and assessments immunological recovery. Five hundred fifty-three HIV-positive antiretroviral-naïve adults, recruited from inner-city clinics, had three serial tests. Test 1 was mostly done a laboratory network supporting primary care while Tests 2 3 were performed tertiary-level...
Screening for renal, hepatic and haematological disorders complicates the initiation of current first-line antiretroviral therapy (ART). Each additional test done adds substantial costs, both through direct laboratory expenses, but also by increasing burden on health workers patients. Evaluating prevalence clinically relevant abnormalities in different population groups could guide decisions about what tests to recommend national guidelines, or local adaptations these. As part enrolment...
Systemic biomarkers of inflammation, including cytokines and chemokines, are potentially useful in the management both HIV infection non-AIDS-defining disorders. However, relatively little is known about utility measurement circulating platelet activation as a strategy to monitor efficacy combination antiretroviral therapy (cART), well persistence systemic inflammation following virally-suppressive HIV-infected persons. These issues have been addressed current study which cohort consisting...